The U.S. Food and Drug Administration has accepted GTC Biotherapeutics Inc.‘s biologics license application for review.
The FDA will review the license application for the Framingham company’s drug ATryn in January. If the license is approved, the company will receive a $2 million milestone payment from Deerfield , Ill.-based Ovation Pharmaceuticals Inc., to which GTC has licensed ATryn. ATryn has already been given priority review and fast track status by the FDA. The company said the FDA could grant GTC a biologics license for ATryn Feb. 7.
ATryn is an anti-clotting protein treatment developed in the milk of genetically modified goats.
